In the wake of the increase in Current Liabilities in the first quarter 2025, Quick Ratio fell to 0.09 below Ladrx Corporation average.

Within Biotechnology & Pharmaceuticals industry 170 other companies have achieved higher Quick Ratio than Ladrx in first quarter 2025. While Quick Ratio total ranking in the first quarter 2025 has deteriorated compared to the prior quarter from 2743 to 4620.

Explain Quick Ratio?
How much Cash & cash equivalents LADX�s has?
What are LADX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LADX Quick Ratio	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1
Y / Y Current Liabilities Change	27.65 %	2.65 %	-12.92 %	-16.95 %	-20.1 %
Y / Y Cash & cash equivalent Change	-89.97 %	-63.3 %	-98.05 %	-77.34 %	240.42 %
Quick Ratio MRQ	0.09	0.34	0.03	0.45	1.1
LADX's Total Ranking	# 4620	# 2743	# 3921	# 2509	# 1140
Seq. Current Liabilities Change	6.02 %	23.52 %	0.05 %	-2.57 %	-14.74 %
Seq. Cash & cash equivalent Change	-72.76 %	1226.92 %	-92.99 %	-60.44 %	-0.28 %

Quick Ratio first quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 171
Healthcare Sector	# 1021
Overall Market	# 4620

Quick Ratio Statistics
High	Average	Low
21.12	3.77	0.03
(Jun 30 2019)		(Sep 30 2024)

Financial Statements
Ladrx's Current Liabilities	$ 2 Millions	Visit LADX's Balance sheet
Ladrx's Cash & cash equivalent	$ 0 Millions	Visit LADX's Balance sheet
Source of LADX's Sales		Visit LADX's Sales by Geography

Cumulative Ladrx's Quick Ratio

LADX's Quick Ratio for the trailling 12 Months

LADX Quick Ratio	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-0.8 %	-11.96 %	-12.49 %	-11.02 %	-10.42 %
Y / Y Cash & cash equivalent TTM Growth	-82.75 %	-59.86 %	-41.21 %	-8.33 %	17.15 %
Quick Ratio TTM	0.22	0.47	0.65	0.98	1.27
Total Ranking TTM	# 3481	# 3551	# 3418	# 3366	# 3495
Seq. Current Liabilities TTM Growth	6.66 %	0.76 %	-3.39 %	-4.45 %	-5.33 %
Seq. Cash & cash equivalent TTM Growth	-50.23 %	-26.16 %	-36.48 %	-26.12 %	15.82 %

Quick ratio ranking by company, industry and sector >> Back to LADX Financial Strength Comparisons >> Go to Compare LADX Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q1 2025 to $2.39 millions, cumulative Quick Ratio decreased to 0.22 below the Ladrx Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 152 other companies have achieved higher Quick Ratio than Ladrx. While Quick Ratio overall ranking has improved so far to 3481, from total ranking during the twelve months ending fourth quarter 2024 at 3551.

Explain Quick Ratio?
How much Cash & cash equivalents LADX�s has?
What are LADX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 153
Healthcare Sector	# 932
Within the Market	# 3481

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.26	3.64	0.22
(Dec 31 2019)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Mar 31 2025 MRQ Cash & cash equivalent	Mar 31 2025 MRQ Current Liabilities
Aim Immunotech Inc	0.24	$ 2.247 Millions	$ 9.533 Millions
Tevogen Bio Holdings Inc	0.23	$ 1.975 Millions	$ 8.549 Millions
Aptose Biosciences Inc	0.23	$ 1.300 Millions	$ 5.714 Millions
Opthea Limited	0.22	$ 55.630 Millions	$ 257.868 Millions
Windtree Therapeutics Inc	0.18	$ 1.173 Millions	$ 6.476 Millions
Xtant Medical Holdings Inc	0.17	$ 5.032 Millions	$ 28.874 Millions
Zeo Scientifix Inc	0.16	$ 0.542 Millions	$ 3.453 Millions
Brainstorm Cell Therapeutics inc	0.15	$ 1.644 Millions	$ 10.901 Millions
Alvotech	0.14	$ 172.359 Millions	$ 1,262.147 Millions
Vaxart Inc	0.13	$ 13.240 Millions	$ 98.504 Millions
Armata Pharmaceuticals Inc	0.11	$ 11.688 Millions	$ 110.540 Millions
Tradeup Acquisition Corp	0.10	$ 0.421 Millions	$ 4.275 Millions
Agenus Inc	0.09	$ 18.488 Millions	$ 208.304 Millions
Ladrx Corporation	0.09	$ 0.207 Millions	$ 2.395 Millions
Atlantic Coastal Acquisition Corp Ii	0.06	$ 1.327 Millions	$ 20.608 Millions
Scilex Holding Company	0.02	$ 5.800 Millions	$ 275.744 Millions
Futuretech Ii Acquisition Corp	0.02	$ 0.131 Millions	$ 7.336 Millions

Date modified: 2026-09-08T15:11:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.